Literature DB >> 14632968

Application of artificial neural network modelling to identify severely ill patients whose aminoglycoside concentrations are likely to fall below therapeutic concentrations.

S Yamamura1, R Takehira, K Kawada, K Nishizawa, S Katayama, M Hirano, Y Momose.   

Abstract

OBJECTIVE: Identification of ICU patients whose concentrations are likely to fall below therapeutic concentrations using artificial neural network (ANN) modelling and individual patient physiologic data.
METHOD: Data on indicators of disease severity and some physiologic data were collected from 89 ICU patients who received arbekacin (ABK) and 61 who received amikacin (AMK). Three-layer ANN modelling and multivariate logistic regression analysis were used to predict the plasma concentrations of the aminoglycosides (ABK and AMK) in the severely ill patients.
RESULTS: Predictive performance analysis showed that the sensitivity and specificity of ANN modelling was superior to multivariate logistic regression analysis. For accurate modelling, a predictable range should be inferred from the data structure before the analysis. Restriction of the predictable region, based on the data structure, increased predictive performance.
CONCLUSION: ANN analysis was superior to multivariate logistic regression analysis in predicting which patients would have plasma concentrations lower than the minimum therapeutic concentration. To improve predictive performance, the predictable range should be inferred from the data structure before prediction. When applying ANN modelling in clinical settings, the predictive performance and predictable region should be investigated in detail to avoid the risk of harm to severely ill patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14632968     DOI: 10.1046/j.0269-4727.2003.00514.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  6 in total

1.  Spline functions in convolutional modeling of verapamil bioavailability and bioequivalence. I: conceptual and numerical issues.

Authors:  J Popović
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2006 Apr-Jun       Impact factor: 2.441

2.  Population pharmacokinetic and pharmacodynamic models of remifentanil in healthy volunteers using artificial neural network analysis.

Authors:  S H Kang; M R Poynton; K M Kim; H Lee; D H Kim; S H Lee; K S Bae; O Linares; S E Kern; G J Noh
Journal:  Br J Clin Pharmacol       Date:  2007-02-23       Impact factor: 4.335

3.  Artificial neural network to predict skeletal metastasis in patients with prostate cancer.

Authors:  Jainn-Shiun Chiu; Yuh-Feng Wang; Yu-Cheih Su; Ling-Huei Wei; Jian-Guo Liao; Yu-Chuan Li
Journal:  J Med Syst       Date:  2009-04       Impact factor: 4.460

4. 

Authors:  Laura Gosselin; Maxime Thibault; Denis Lebel; Jean-François Bussières
Journal:  Can J Hosp Pharm       Date:  2021-04-01

5.  Application of Machine Learning for Tumor Growth Inhibition - Overall Survival Modeling Platform.

Authors:  Phyllis Chan; Xiaofei Zhou; Nina Wang; Qi Liu; René Bruno; Jin Y Jin
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2020-12-13

6.  Artificial Neural Network Modeling of Quality of Life of Cancer Patients: Relationships between Quality of Life Assessments, as Evaluated by Patients, Pharmacists, and Nurses.

Authors:  Rieko Takehira; Keiko Murakami; Sirou Katayama; Kenji Nishizawa; Shigeo Yamamura
Journal:  Int J Biomed Sci       Date:  2011-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.